AstraZeneca

A→Z catalog of AstraZeneca

A

• Airsupra — Albuterol/budesonide — As-needed anti-inflammatory reliever for asthma — 2 inhalations as needed; usual max 6 doses/day.

• Accolate — Zafirlukast — Asthma maintenance — 20 mg BID on empty stomach.

• Adasuve (select regions legacy) — Loxapine inhalation — Agitation in schizophrenia/bipolar — 10 mg inhaled once PRN (facility use).

• Alna/Alfuzosin AZ brands (regional) — Alfuzosin — BPH — 10 mg QD (XR).

• Andexxa / Ondexxya — Andexanet alfa — Reversal of apixaban/rivaroxaban life-threatening bleeding — IV bolus then 2-hr infusion per regimen.

• Arimidex — Anastrozole — HR+ breast cancer — 1 mg QD.

• Atacand — Candesartan cilexetil — Hypertension, heart failure — 8–32 mg QD (HF often 32 mg QD).

• Atacand Plus — Candesartan/HCTZ — Hypertension — 16/12.5 mg or 32/12.5–25 mg QD.

• Axanum (select EU) — Esomeprazole/aspirin co-pack — CV prevention + GI protection — Per pack instructions.

B

• Bevespi Aerosphere — Glycopyrrolate/formoterol — COPD maintenance — 2 inhalations BID.

• Betaloc — Metoprolol tartrate — Hypertension/angina/arrhythmia — 50–100 mg BID.

• Betaloc ZOK / Seloken ZOK — Metoprolol succinate — HTN/HF — 25–200 mg QD (HF start low, titrate).

• Bricanyl — Terbutaline — Bronchospasm relief — 0.25–0.5 mg inhaled PRN (or tabs/syrup per label).

• Breztri Aerosphere — Budesonide/glycopyrrolate/formoterol — COPD maintenance — 2 inhalations BID.

• Brilinta / Brilique — Ticagrelor — ACS, post-MI — 90 mg BID (ACS) then often 60 mg BID maintenance.

C

• Calquence — Acalabrutinib — CLL/SLL, MCL (regions) — 100 mg BID.

• Caprelsa — Vandetanib — Medullary thyroid cancer — 300 mg QD.

• Casodex — Bicalutamide — Prostate cancer — 50 mg QD (or 150 mg QD per label/setting).

• Cerdelga co-rights (regional legacy) — Eliglustat — Gaucher type 1 — 84 mg BID (genotype-dependent).

• Crestor — Rosuvastatin — Hyperlipidemia — 5–40 mg QD.

• Combglyze XR / Komboglyze — Saxagliptin/metformin XR — Type 2 diabetes — Per strength QD with food.

D

• DuoResp Spiromax / Symbicort generics brand variant (some EU) — Budesonide/formoterol — Asthma/COPD — Typical 1–2 inhalations BID.

• Duralone regional pack — Prednisone/others — Steroid taper packs — Per pack schedule.

• Dapagliflozin (Farxiga/Forxiga) — see F.

E

• Enhertu (co-commercialized) — Trastuzumab deruxtecan — HER2+ (and HER2-low) cancers — IV q3w per body weight.

• Eklira co-legacy (aclidinium) in some markets — COPD — 400 µg BID.

• Esomeprazole (Nexium) — Esomeprazole — GERD/erosive esophagitis — 20–40 mg QD.

• Evusheld — Tixagevimab/cilgavimab — Pre-exposure COVID-19 prophylaxis (region-dependent) — IM doses per current label.

F

• Fasenra — Benralizumab — Severe eosinophilic asthma — 30 mg SC at 0, 4 weeks, then q8w (pre-filled pen/syringe).

• Farxiga / Forxiga — Dapagliflozin — T2D, HFrEF/HFpEF, CKD — 10 mg QD.

• Faslodex — Fulvestrant — HR+ breast cancer — 500 mg IM Days 1, 15, 29 then q28d.

• Fluenz Tetra / FluMist Quadrivalent — Live attenuated influenza vaccine (LAIV) — Influenza prevention — 0.2 mL intranasal once per season.

• Formoterol (Oxis Turbuhaler) — Formoterol fumarate — Bronchodilation — 6–12 µg inhaled BID (per label).

G

• Galvus co-rights (regional legacy) — Vildagliptin — T2D — 50 mg BID or 50 mg QD (with metformin).

• Gefitinib (Iressa) — Gefitinib — EGFR-mutated NSCLC — 250 mg QD.

• Goserelin (Zoladex) — Goserelin — Prostate/breast cancer, endometriosis — 3.6 mg q28d or 10.8 mg q12w implant.

H

• Helicobacter pylori triple packs (Nexium HP7 / Nexium HP Triple) — Esomeprazole + amoxicillin + clarithromycin — H. pylori eradication — Per pack BID regimens 7–14 days.

• Hylidor (regional) — Hydralazine — Hypertension — 25–100 mg BID–QID.

I

• Imdur — Isosorbide mononitrate — Angina prophylaxis — 30–60 mg QD (ER) or divided IR.

• Imfinzi — Durvalumab — NSCLC (stage III), SCLC, BTC, HCC, others — IV q2–4w per indication.

• Imjudo — Tremelimumab — With durvalumab in HCC/NSCLC — IV per combo schedule.

• Iressa — see G.

J

• (none widely used beginning with J; see other letters for oncology/respiratory)

K

• Kanuma — Sebelipase alfa — Lysosomal acid lipase deficiency — IV every 1–2 weeks.

• Koselugo — Selumetinib — Pediatric NF1 plexiform neurofibromas — 25 mg/m² BID (capsules).

L

• Lokelma — Sodium zirconium cyclosilicate — Hyperkalemia — 10 g TID for up to 48 h then maintenance QD or 2–3×/wk.

• Losec / Prilosec — Omeprazole — GERD, ulcers — 20–40 mg QD.

• Lynparza — Olaparib — Ovarian, breast, prostate, pancreatic cancers (selected mutations) — 300 mg BID (tabs) or 400 mg BID (caps in older labels).

M

• Merrem IV — Meropenem — Serious bacterial infections — 1 g IV q8h (dose/interval per infection/renal).

• Movantik / Moventig — Naloxegol — Opioid-induced constipation — 25 mg QD (12.5 mg if needed).

• Metoprolol brands (Seloken, Betaloc) — see B.

N

• Nexium — see E.

• Nolvadex — Tamoxifen — HR+ breast cancer — 20 mg QD.

• Nimbex legacy (most territories divested; limited availability) — Cisatracurium — Neuromuscular blockade — Specialist dosing.

O

• Onglyza — Saxagliptin — T2D — 5 mg QD (2.5 mg if renal impairment).

• Orpathys — Savolitinib — MET-altered NSCLC (select regions, often with osimertinib per label) — 300 mg QD (varies).

• Oxis Turbuhaler — see F.

P

• Plendil — Felodipine — Hypertension — 5–10 mg QD (ER).

• Pulmicort (Turbuhaler/Respules) — Budesonide — Asthma maintenance — Inhaled doses BID (per device/strength).

Q

• Qtern — Dapagliflozin/saxagliptin — T2D — 10/5 mg QD.

• Qternmet XR — Dapagliflozin/saxagliptin/metformin XR — T2D — Per strength QD with food.

R

• Rhinocort Aqua (select markets) — Budesonide nasal — Allergic rhinitis — 1–2 sprays/nostril QD.

• Roxadustat (China co-promotion) — Roxadustat — Anemia in CKD — Oral dosing 2–3×/week per hemoglobin/label.

S

• Saphnelo — Anifrolumab-fnia — Moderate-to-severe SLE — 300 mg IV q4w (auto-injector SC where approved).

• Seloken / Seloken ZOK — Metoprolol succinate — see B.

• Seroquel — Quetiapine — Schizophrenia, bipolar, MDD adjunct — 150–800 mg/day (XR or IR split).

• Seroquel XR — Quetiapine XR — As above — Once-daily titration to target.

• Soliris — Eculizumab — PNH, aHUS, gMG, NMOSD — IV induction then q2w maintenance.

• Strensiq — Asfotase alfa — Hypophosphatasia — SC several times/week by wt.

• Symbicort (Turbohaler/pMDI) — Budesonide/formoterol — Asthma/COPD; also anti-inflammatory reliever regimens — Typical 1–2 inhalations BID (or AIR use per label).

T

• Tagrisso — Osimertinib — EGFR-mutated NSCLC (metastatic/adjuvant) — 80 mg QD.

• Tenormin — Atenolol — Hypertension/angina — 25–100 mg QD.

• Tenoretic — Atenolol/chlorthalidone — Hypertension — 50/12.5 mg or 100/25 mg QD.

• Tezspire (with Amgen) — Tezepelumab-ekko — Severe asthma — 210 mg SC q4w.

• Truqap — Capivasertib — HR+, HER2- advanced breast cancer with AKT-pathway alterations (with fulvestrant) — 400 mg BID, 4-days-on/3-days-off.

• Toprol-XL (select markets) — Metoprolol succinate — see B.

U

• Ultomiris — Ravulizumab — PNH, aHUS, gMG — IV loading then q8w maintenance (wt-based).

V

• Vimovo — Naproxen/esomeprazole — Pain/arthritis + GI protection — 375/20 or 500/20 mg BID.

• Voydeya — Danicopan — Add-on for PNH with extravascular hemolysis on C5 inhibitor — 150–200 mg TID (per label).

• Vandetanib — see Caprelsa.

W

• Wainua — Eplontersen — hATTR polyneuropathy — 45 mg SC q4w (after 3 monthly loading doses where applicable).

X

• Xigduo / Xigduo XR — Dapagliflozin/metformin (IR/XR) — T2D — Per strength BID (IR) or QD (XR).

• Xylometazoline AZ regional OTCs (limited) — Xylometazoline — Nasal decongestant — 1 spray/nostril q8–10h (short-term).

Y

• (none widely used beginning with Y)

Z

• Zestril — Lisinopril — Hypertension/HF — 5–40 mg QD.

• Zoladex — Goserelin — see G.

• Zomig (select markets legacy) — Zolmitriptan — Migraine — 2.5–5 mg at onset; may repeat ≥2 h (max/day per label).